Form 8-K Coherus BioSciences, For: Dec 26
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Coherus BioSciences (CHRS) surges on FDA Udenyca delivery system approval
December 27, 2023 7:57 AM ESTShares of Coherus BioSciences (NASDAQ: CHRS) surged 35% in trading on Wednesday after the company announced the U.S. Food and Drug Administration (FDA) approved its UDENYCA ONBODY product.
UDENYCA ONBODY is the company's on-body injector (OBI) presentation of UDENCYA, designed for a five-minute injection time. The device features an automatic retractable needle mechanism.
"The on-body... More
